September 29, 2016 / 1:26 PM / a year ago

BRIEF-Gabather gets SEK 10 mln for development of drug candidate GT-002

Sept 29 (Reuters) - Gabather AB :

* Says has signed a consortium agreement for clinical development of its drug candidate GT-002 together with partner companies Pharmaterials, Smerud and CRST

* Cooperation starts in October and lasts until Phase 2a or a total of three years

* The agreement gives a net contribution from local EU authorities to cooperation of about 10 million Swedish crowns ($1.16 million)

* Other costs are paid by the participating parties

Source text: bit.ly/2du1P4h

Further company coverage: ($1 = 8.5880 Swedish crowns) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below